- Home
- EOLS
EOLS
Evolus Inc.
as 04-18-2025 1:35pm EST
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEWPORT BEACH |
| Market Cap: | N/A | IPO Year: | 2018 |
| Target Price: | $23.75 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.81 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.67 - $17.82 | Next Earning Date: | 05-06-2025 |
| Revenue: | $266,274,000 | Revenue Growth: | 31.76% |
| Revenue Growth (this year): | 34.79% | Revenue Growth (next year): | 32.95% |
Stock Insider Trading Activity of Evolus Inc. (EOLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MOATAZEDI DAVID | EOLS | See Remarks | Mar 27 '25 | Sell | $12.40 | 6,251 | $77,512.40 | 508,619 | |
| Beaver Sandra | EOLS | Chief Financial Officer | Mar 18 '25 | Sell | $13.26 | 8,996 | $119,242.88 | 173,583 | |
| Yamagishi-Dressler Tomoko | EOLS | Chief Marketing Officer | Mar 18 '25 | Sell | $13.26 | 4,536 | $60,124.68 | 95,671 | |
| MOATAZEDI DAVID | EOLS | See Remarks | Mar 18 '25 | Sell | $13.26 | 103,376 | $1,370,248.88 | 508,619 | |
| Avelar Rui | EOLS | See Remarks | Mar 18 '25 | Sell | $13.26 | 27,904 | $369,867.52 | 362,467 | |
| Parschauer Karah Herdman | EOLS | Director | Mar 12 '25 | Sell | $12.99 | 12,888 | $167,465.38 | 32,183 |
Latest Evolus Inc. News
EOLS Breaking Stock News: Dive into EOLS Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
BTIG Initiates Evolus at Buy With $21 Price Target
Business Wire
3 days ago
Evolus Announces Commercial Launch of Evolysse™
Business Wire
4 days ago
Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse™ Injectable Hyaluronic Acid Gels
Business Wire
25 days ago
Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference
Simply Wall St.
a month ago
Investing in Evolus (NASDAQ:EOLS) five years ago would have delivered you a 216% gain
Business Wire
a month ago
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
a month ago
Evolus Insider Sold Shares Worth $1,370,249, According to a Recent SEC Filing
Motley Fool
a month ago
Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas
Compare EOLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EOLS Evolus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.